alexa Intervention On Viral Diseases By Targeting Host Cellular Factors: A Novel Approach
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Franco Lori
ScientificTracks Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.020
Abstract
Viruses are intracellular parasites which carry a limited set of genetic information and therefore are completely dependent on the host cells they infect to propagate and survive. While antivirals have traditionally been designed to directly target viral proteins in search for specificity and good therapeutic indices, some virus-targeted drugs have been plagued with issues of toxicity that have severely limited their ability to be developed and utilized as therapeutics. Moreover, a common drawback for all such direct-acting antivirals is the emergence of resistance, resulting from rapid mutations of viral proteins. An alternative approach to the direct-acting antivirals is to target the key cellular proteins that are essential for viral replication and survival. This approach helps to address the issue of resistance since cellular proteins are less prone to mutate than virally encoded ones. The perception that toxicity is an issue when targeting cellular factors is a misconception. In reality, the majority of drugs used in the past and in current medical treatments target cellular mechanisms. Significantly, these drugs have been used safely and efficaciously on millions of individuals, and many drugs targeting cellular factors can be safely used chronically, often for decades (e.g. anti-hypertensive, anti-cholesterol, etc.), a distinct advantage for the treatment of chronic viral infections. Given the above, at ViroStatics we have focused our efforts on developing a new class of drugs that target viruses through the inhibition of host cellular factors. In this regard, we are pursuing the novel approach of targeting the cellular kinase CDK9 (Cyclin-Dependent Kinase 9), which is known to play an essential role for viral replication and survival in a number of infections, including HIV, EBV, HSV and HPV. While there is a broad applicability to this approach, our initial focus has been on the indication for HIV/AIDS. We are developing first-in-class Transcription Inhibitors designed to attack the unexploited, post-integration phases of HIV replication through CDK9 inhibition. HIV/AIDS offers a natural proof of concept in support to this notion: Elite Controllers, a low percentage of untreated HIV infected individuals with an undetectable HIV RNA load, exhibit an intrinsic inhibition of CDK9 activity which occurs without any apparent safety issues or the induction of viral resistance. ViroStatics? compounds are designed to mimic this Elite Controllers? phenotype, in essence, to pharmacologically induce ?elite control? that rarely occurs naturally. Some ViroStatics? CDK9 inhibitors suppress HPV replication in vitro with an antiviral potency up to a thousand-fold higher than the reference control drug Cidofovir. Initial screening has shown good druggability and safety profiles of CDK9 inhibitors both in vitro and in vivo. The absolute dependence of any virus on the host cellular machinery for propagation and survival represents the Achilles? heel for all viruses. Developing cell-targeted drugs as an alternative to virus-targeted drugs would provide a new generation of antivirals that addresses the continued unmet need of drug resistance and offers the potential for new medicines for infections that cannot be presently treated.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords